Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases

Vandana Singh
1 min read
0
In this article:

  • Kala Pharmaceuticals Inc (NASDAQ: KALA) reported data from a Phase 1b trial of KPI-012, a cell-free secretome therapy for severe ocular diseases driven by impaired healing.

  • As previously disclosed, KPI-012 was well tolerated and resulted in significant improvements in various persistent corneal epithelial defect (PCED) etiologies.

  • The data will be presented at the 2022 Association for Research in Vision and Ophthalmology.

  • KPI-012 resulted in the complete healing of PCED in 6 of 8 participants.

  • Improvement in PCED lesion size was observed in those participants who did not heal completely.

  • All six healed participants remained healed through the end of the follow-up.

  • Related: This Microcap Pharma Stock Almost Doubled Today - Read Why.

  • Participants had a mean (SD) improvement in lesion size of -16.23 (12.38) mm2.

  • The mean improvement in BCDVA was -0.38 (0.88) logMAR.

  • 5 of 8 participants (62.5%) improved their corneal opacity scores from baseline to end of treatment, and 1 had no change in score.

  • 100% reported pain reduction by Week 1. There was only one TEAE reported, and it was mild and transient

  • The company is on track to submit FDA Investigational New Drug Application (IND) and initiate the Phase 2/3 Trial in 4Q 2022.

  • Price Action: KALA shares are up 9.31% at $0.71 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories